DDInter576 DDInter342
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms (acetaldehyde syndrome). It acts by inhibiting aldehyde dehydrogenase.
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019.
Disulfiram {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Betamethasone
Betamethasone {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Disulfiram {u} (Compound) binds {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) is bound by {v} (Compound) Dapsone
Dapsone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Disulfiram {u} (Compound) upregulates {v} (Gene) FHL2
FHL2 {u} (Gene) is upregulated by {v} (Compound) Irinotecan
Irinotecan {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Disulfiram {u} (Compound) upregulates {v} (Gene) IL11
IL11 {u} (Gene) is downregulated by {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Disulfiram {u} (Compound) upregulates {v} (Gene) FHL2
FHL2 {u} (Gene) is downregulated by {v} (Compound) Fluvastatin
Fluvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Disulfiram {u} (Compound) upregulates {v} (Gene) NFKB2
NFKB2 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Disulfiram {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is bound by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Certolizumab pegol
Disulfiram {u} (Compound) upregulates {v} (Gene) TUBB6
TUBB6 {u} (Gene) is bound by {v} (Compound) Ixabepilone
Ixabepilone {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Disulfiram {u} (Compound) upregulates {v} (Gene) SLC7A11
SLC7A11 {u} (Gene) is bound by {v} (Compound) Rosuvastatin
Rosuvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Disulfiram {u} (Compound) downregulates {v} (Gene) NR2F6
NR2F6 {u} (Gene) is downregulated by {v} (Compound) Bortezomib
Bortezomib {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Disulfiram (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Betamethasone (Compound) and Betamethasone may lead to a major life threatening interaction when taken with Certolizumab pegol
Disulfiram (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Dapsone (Compound) and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Disulfiram (Compound) upregulates FHL2 (Gene) and FHL2 (Gene) is upregulated by Irinotecan (Compound) and Irinotecan may lead to a major life threatening interaction when taken with Certolizumab pegol
Disulfiram (Compound) upregulates IL11 (Gene) and IL11 (Gene) is downregulated by Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Certolizumab pegol
Disulfiram (Compound) upregulates FHL2 (Gene) and FHL2 (Gene) is downregulated by Fluvastatin (Compound) and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Disulfiram (Compound) upregulates NFKB2 (Gene) and NFKB2 (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Disulfiram (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is bound by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Disulfiram (Compound) upregulates TUBB6 (Gene) and TUBB6 (Gene) is bound by Ixabepilone (Compound) and Ixabepilone may lead to a major life threatening interaction when taken with Certolizumab pegol
Disulfiram (Compound) upregulates SLC7A11 (Gene) and SLC7A11 (Gene) is bound by Rosuvastatin (Compound) and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Disulfiram (Compound) downregulates NR2F6 (Gene) and NR2F6 (Gene) is downregulated by Bortezomib (Compound) and Bortezomib may lead to a major life threatening interaction when taken with Certolizumab pegol